Exploratory analysis in DEN-181–treated patients found that improved RA disease activity correlated with expansion of CII-specific and Cit-Vim–specific T cells; reduction in ACPA VDG, memory B cells, and inflammatory myeloid populations; and enrichment in proportions of CCR7+ and naive T cells in peripheral blood (PB). Here, PRTN3 is linked to rheumatoid arthritis.